
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Oct 27, 2026
Resale registration declared effective
$WORXHealthcare data and softwareDated financialsExecution and funding risk
WORX Stock Hub: SCWorx News, Operations and Capital
New hospital customers and a leaner delivery model support the operating recovery. June cash was $1.263 million, but financing terms, warrant uncertainty and Nasdaq monitoring remain central to the common-share case. The October 30, 2026 regular-session close was $1.60. Historical financial and clinical observations retain the dates shown below.
Full research report · PDF
SCWorx ($WORX), research as of October 27, 2026
18 pages covering The archive examines SCWorx’s healthcare-data business and the economics of new software workflows. It sets revenue, losses and liquidity against Nasdaq monitoring, warrant exercises and resale registration, explaining dilution and the limits of interpreting registration capacity as company cash. This is dated research; the hub follows later developments. For personal use only: redistribution prohibited.
Next financial and operating checkpoint
Next financial report · date not announced
The next financial report will test whether healthcare engagements and delivery-cost savings support revenue and cash conversion. Company disclosure
Resale registration is effective and a final prospectus was filed October 27. Issued shares, potential warrant shares, holder resale proceeds and possible company cash exercises remain separate. The Nasdaq Panel Monitor continues through October 2, 2027.
WORX stock at a glance
Close · October 30, 2026
$1.60
Regular session; -12.09% versus $1.8200 on October 29.
Common shares
1,387,099
October 21, 2026 in the October 27 final prospectus; excludes unissued warrant shares. Final prospectus
Where SCWorx stands now
H1 2026 revenue rose 3.4% to $1.451 million; calculated gross margin reached 48.6%, but operating loss remained $256,768. Operations and capitalized software used a combined $396,463. September funding improved resources at a substantial ownership and contractual cost. [1] [7]
The main constraint. Revenue growth remains modest, the business still consumes cash and customer concentration is material. Warrants, resale capacity, inconsistent capital disclosures and limited Nasdaq cure protections can outweigh operating progress for existing common shareholders. [1] [10] [9]
The constructive case
Lower delivery costs lifted H1 gross profit to $704,532, and new customer relationships create room for incremental revenue. If onboarding, retention and cash collection improve without a matching cost increase, the business could move closer to sustainable profitability. [1] [5]
Latest SCWorx news
Oct 27, 2026
Resale registration declared effective
An SEC notice of effectiveness (EFFECT) shows that the Form S-3 resale registration statement (File No. 333-299494) became effective on October 26, 2026 at 5:00 p.m. ET. The last amendment before effectiveness (S-3/A, October 23) covers the resale by selling stockholders of up to 8,253,352 shares: 399,860 shares already issued in the September placement and up to 7,853,492 shares issuable on exercise of warrants, against about 13.0 million in the original October 16 filing (13,099,253 on the cover, 12,999,253 in the offering summary). SCWorx will not receive proceeds from the resales; it would receive the exercise price of warrants exercised for cash, which the amended prospectus puts at up to about $20.1 million if all were exercised for cash (about $32.5 million in the original). The prospectus reports 1,387,099 common shares outstanding on October 22, 2026, and says that warrants other than the September series contain provisions that can reduce the exercise price and increase the number of underlying shares. On October 27, 2026 SCWorx filed the final prospectus (Form 424B3) for the resale. It covers up to 8,253,352 shares: 399,860 shares already issued (350,000 sold to purchasers and 49,860 issued to the placement agent as compensation under the September 16, 2026 securities purchase agreement) and up to 7,853,492 shares issuable on exercise of warrants, made up of 2,055,530 July 2024 warrants, 165,618 November 2024 warrants, 4,282,458 January 2025 warrants, 999,886 inducement warrants and 350,000 September 2026 warrants. The company will not receive proceeds from the resales and could receive up to about $20.1 million if all warrants were exercised for cash, to be used for working capital and general corporate purposes; some warrants may be exercised on a cashless basis. The prospectus counts 1,387,099 shares outstanding on October 21, 2026 and 9,240,591 after the offering if all the warrant shares were issued, and reports a last sale price of $2.61 on the Nasdaq Capital Market on October 22. Form 424B3
Oct 23, 2026
Amended resale registration narrows share coverage
The amendment covers up to 8,253,352 shares, separating already-issued stock from warrant shares. The later October 27 final prospectus follows effectiveness; resale proceeds do not go to the company.
Oct 19, 2026
New healthcare-system customer
Agreement supports product-data accuracy, completeness and usability across a southwestern health-system relationship. Financial terms were undisclosed.
Oct 16, 2026
Resale registration filed
Preliminary S-3 covers issued shares and warrant-related stock. Resale capacity is not funded cash or a current issued-share total.
Oct 7, 2026
Nasdaq trading resumed
The reopening followed the Panel reconsideration decision; a one-year monitor and monthly reporting remain in place.
Sep 16, 2026
Equity-and-warrant financing closed
350,000 shares plus matching warrants raised $938,000 gross. Placement-agent stock and existing-warrant exercises separately expanded issued stock.
WORX stock catalysts: operating and financial milestones
- Date not announced — Next quarterly financial results. Official calendar checked; no dated release
- October 2, 2027 — End of one-year Nasdaq Panel Monitor period. Disclosed monitoring horizon
October 27, 2026 disclosure October 19, 2026 disclosure October 16, 2026 disclosure
WORX stock scenarios: an operating recovery meets a difficult capital structure
The constructive scenario starts with an observable change in delivery economics rather than with a large addressable-market estimate. In the first half of 2026, SCWorx generated $704,532 of gross profit on $1,450,948 of revenue. Revenue increased only modestly, but lower contractor and hosting costs allowed a much larger share of each sales dollar to contribute toward overhead. If that delivery structure proves durable, additional customer revenue could narrow the operating deficit without requiring an equivalent increase in personnel and infrastructure. The essential condition is profitable service delivery, not simply more contracts. [1] The customer announcements provide possible routes to that outcome. A Florida teaching hospital selected SCWorx for data preparation supporting a Workday implementation; a Massachusetts integrated delivery network entered a two-year agreement; and the October announcement added a community-owned health system serving four southwestern states. These are commercial relationships with different implementation and revenue profiles. A favorable outcome would combine successful onboarding, continuing service requirements and collections, while retaining existing customers. The announcements establish customer additions, but their undisclosed economics leave the size of their eventual contribution open. [2] [4] [5]
What does SCWorx do? Healthcare product data, not drug development
SCWorx Corp. is a Delaware corporation headquartered in Middleton, Massachusetts. Its operating business provides healthcare data-management technology and services to U.S. hospitals and health systems. The current public company took the SCWorx name following the February 2019 transaction in which Alliance MMA acquired the healthcare-data business. The ticker’s corporate history therefore reaches beyond the present operating model. The relevant business today is the organization, enrichment and exchange of healthcare product information, rather than biotechnology research or a pharmaceutical pipeline. [10] The practical problem is an item master: the database a hospital uses to identify the products it purchases and consumes. Different departments, suppliers and applications may use inconsistent descriptions, classifications or identifiers for the same item. Missing attributes and duplicate records can make it harder to compare prices, enforce purchasing contracts, track utilization or connect clinical consumption with financial records. SCWorx’s platform is designed to repair and standardize that underlying information so that different enterprise applications can work with a more consistent product record. Those are the intended benefits of the service, not a guarantee of a particular savings rate at every customer. [1] [10]
Merlintrader Health Score · $WORX
1.95out of 5
Assessed October 27, 2026. Weighted calculation: 2.5×30% + 2.0×30% + 1.0×20% + 1.5×10% + 2.5×10% = 1.95. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.
Red flags
- Historical cash is not a current cash balance; subsequent spending and financing matter.
- Company milestones remain conditional where explicitly identified as plans or targets.
- Revenue growth remains modest, the business still consumes cash and customer concentration is material. Warrants, resale capacity, inconsistent capital disclosures and limited Nasdaq cure protections can outweigh operating progress for existing common shareholders. [1] [10] [9]
WORX Stock FAQ: SCWorx Questions Answered
What is the next catalyst for WORX stock?
As of November 3, 2026, SCWorx has not yet dated its next quarterly results. Its Nasdaq Panel Monitor runs through October 2, 2027; a continued-listing failure during that period can trigger a delisting determination without the usual compliance-plan or cure-period process. SCWorx investor calendar. October 5 Nasdaq disclosure.
Is SCWorx profitable and how much revenue does WORX make?
SCWorx reported $1,450,948 of revenue for the six months ended June 30, 2026, but remained unprofitable. Gross profit was $704,532, operating loss was $256,768 and net loss was $294,721 for that same six-month period. June 2026 Form 10-Q.
How much cash does WORX have?
SCWorx held $1,263,478 in cash at June 30, 2026. Operating activities used $258,442 during the first half, while capitalized software used a separate $138,021. The September 16 financing raised $938,000 gross, but its agreement required the proceeds to remain in a segregated account for 90 days after closing. June 2026 cash-flow statement. September financing disclosure. Securities purchase agreement, section 4.19.
How many WORX shares and warrants could be sold?
SCWorx’s October 27, 2026 prospectus covered resale of 399,860 outstanding shares and up to 7,853,492 shares potentially issuable through warrant exercises. Common shares outstanding were 1,387,099 as of October 21. SCWorx receives no proceeds from holder resales; only cash warrant exercises would provide exercise proceeds to the company. October 27 resale prospectus.
When will SCWorx report its next earnings?
As of November 3, 2026, SCWorx had not announced a date for its next quarterly earnings release. Its most recent filed quarterly financial statements cover the three and six months ended June 30, 2026. SCWorx news releases. SCWorx investor calendar. Latest Form 10-Q.
What does SCWorx do?
SCWorx sells healthcare data-management software and services to hospitals and health systems, as described in its October 19, 2026 announcement. Its platform cleans, standardizes, enriches and maintains healthcare product data so customers can use consistent information across supply-chain, finance, clinical and enterprise applications. SCWorx services and customer announcement.
Is WORX trading on Nasdaq again?
Yes. WORX resumed trading on the Nasdaq Capital Market on October 7, 2026, as confirmed in SCWorx’s October 27 prospectus. Continued listing remains conditional, including a one-year Panel Monitor ending October 2, 2027. Nasdaq trading and listing conditions.
Who are SCWorx’s new customers and is Workday a partner?
SCWorx announced a community-owned health-system customer on October 19, 2026, and a Florida teaching-hospital customer on June 30. The health system serves New Mexico, Arizona, Colorado and Utah. The Florida hospital bought data services supporting its Workday implementation; the announcement describes a hospital contract, not a corporate partnership with Workday. Financial terms were undisclosed. October 19 health-system agreement. June 30 hospital agreement.
Primary sources
- October 27, 2026 — Resale registration declared effective
- October 23, 2026 — Amended resale registration narrows share coverage
- October 19, 2026 — New healthcare-system customer
- October 16, 2026 — Resale registration filed
- October 7, 2026 — Nasdaq trading resumed
- September 16, 2026 — Equity-and-warrant financing closed
Disclaimer. Published by Merlintrader for educational and informational purposes only. This content is not investment advice, an investment recommendation, an offer or a solicitation to buy or sell securities. The analysis and Health Score are editorial interpretations, not a price target or a guarantee of future performance.
Company expectations and scenarios remain uncertain. Financial and market figures carry their own reference dates and may change. Small companies can face customer concentration, financing, dilution, technology, accounting and exchange-listing risks. Trading can result in loss of part or all of the capital invested. Readers should conduct their own research and consult a licensed financial adviser where appropriate.
Research and organization are supported by artificial intelligence under editorial supervision. Some links are affiliate links and may generate a commission at no additional cost to the reader. See the disclaimer and terms of use and privacy.



